Johnson & Johnson MedTech final week introduced outcomes from a examine of its Monarch platform for robotic bronchoscopy procedures.
Outcomes from the TARGET examine confirmed that clinicians may attain small and peripherally positioned lung nodules in additional than 98% of instances with Monarch. In addition they biopsied these nodules with a security profile in contrast with non-robotic bronchoscopy procedures. Investigators printed findings within the journal CHEST.
TARGET checked out 679 sufferers throughout 21 international websites within the U.S., Canada, and Hong Kong, stated Johnson & Johnson MedTech. The examine aimed to measure security, navigation success, and diagnostic yield throughout a broad vary of sufferers in a real-world setting. Investigators reported reaching the lesion with Monarch in 98.7% of instances and a diagnostic yield of 83.2%.
Monarch demonstrates worth of robot-assisted procedures
The investigators stated additionally they realized about variables considerably related to greater diagnostic yield. These embrace a historical past of persistent obstructive pulmonary illness (COPD)/emphysema and the presence of a bronchus signal.
Dr. Faisal Khan, medical director of interventional pulmonary and endoscopy at Franciscan Well being Indianapolis, stated the outcomes “may help increase consciousness of robotic-assisted bronchoscopy as a secure, efficient possibility.” He stated it may increase the usual of look after sufferers.
Monarch allows the usage of minimally invasive, robotic-assisted know-how for peripheral lung procedures. This might enhance the power to entry small, hard-to-reach peripheral lung nodules at an earlier stage and with higher precision.
“Johnson & Johnson is dedicated to producing proof that demonstrates the protection and efficacy of our merchandise and advances innovation in areas with vital unmet wants,” stated Dr. Ray Fryrear, vice chairman of scientific affairs for robotics and digital at Johnson & Johnson MedTech. “Because the pioneers within the area of robotic-assisted bronchoscopy, we’re dedicated to evolving its potential to alter the best way clinicians diagnose and deal with lung most cancers.”
Johnson & Johnson works to deliver OTTAVA to the market
Monarch isn’t the one robotic surgical system Johnson & Johnson is creating. In April, the corporate introduced that it had accomplished the primary instances within the scientific trial for its OTTAVA Robotic Surgical System. The instances mark the primary scientific expertise with the OTTAVA System, it stated.
The U.S. Meals and Drug Administration (FDA) granted OTTAVA an investigational system exemption in late 2024. Johnson & Johnson MedTech stated it designed the system to advance scientific innovation generally surgical procedure, a major a part of its broader surgical procedure enterprise.
Johnson & Johnson MedTech is a unit of New Brunswick, N.J.-based Johnson & Johnson (J&J), which has greater than 100 years of expertise in drugs and surgical know-how. The corporate stated its portfolio consists of robotics, wound closure, adjunctive hemostats, surgical stapling and devices, and digital methods.
Johnson & Johnson MedTech first shared particulars about OTTAVA about 4 years in the past. Since then, it has been comparatively quiet. In October 2021, the corporate pushed again the platform’s growth timeline by about two years, citing a number of elements.
Editor’s observe: This text was syndicated from The Robotic Report sibling website MassDevice.
Now accepting session submissions!
